American Healthcare REIT vs Healthpeak Properties
AHR and DOC side by side, both in miscellaneous investing. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AHR and DOC compare
American Healthcare REIT and Healthpeak Properties are about the same size, with market caps of $12.6B and $13.8B.
On earnings, Healthpeak Properties is cheaper: it trades at 57.1× trailing earnings, against 118× for American Healthcare REIT.
American Healthcare REIT grew revenue faster over the last twelve months (21.5% versus 5.5% for Healthpeak Properties).
Healthpeak Properties keeps more of each dollar of sales as profit, with a net margin of 8.2% compared with 3.6% at American Healthcare REIT.
Both pay dividends: American Healthcare REIT yields 1.7% and Healthpeak Properties 6.1%.
American Healthcare REIT scores higher on the StockData Score (11 against 9 for Healthpeak Properties), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AHR | DOC |
|---|---|---|
| Size and price | ||
| Market cap | $12.6B | $13.8B |
| Share price | $57.78 | $19.98 |
| Change, 1 year | 20.7% | 13.3% |
| Change, 5 years | – | −41.6% |
| Beta (5Y) | 0.44 | 0.70 |
| Employees | 121 | 411 |
| StockData Score | ||
| Total score | 11 (better) | 9 |
| Valuation score | 0 | 1 (better) |
| Growth score | 5 (better) | 4 |
| Performance score | 3 (better) | 1 |
| Health score | 2 (better) | 0 |
| Dividend score | 1 | 3 (better) |
| Valuation | ||
| P/E | 118× | 57.1× (better) |
| P/S | 4.7× | 4.7× (better) |
| P/B | 2.3× | 1.8× (better) |
| EV/EBITDA | 15.1× | 7.3× (better) |
| Fair value | $23.44 | $16.76 |
| Margin of safety | −146% | −19.2% (better) |
| Growth | ||
| Revenue growth (TTM) | 21.5% (better) | 5.5% |
| Revenue growth, 5Y average | 16.2% (better) | 11.4% |
| Net income growth (TTM) | 253% (better) | 47.5% |
| EPS growth (TTM) | 250% (better) | 45.8% |
| EPS growth, 5Y average | 53.1% (better) | −33.5% |
| Profitability | ||
| Gross margin | 22.1% | – |
| Operating margin | 20.2% | – |
| Net margin | 3.6% | 8.2% (better) |
| Return on equity | 2.3% | 3.1% (better) |
| Return on invested capital | 13.7% | – |
| Financial health | ||
| Interest coverage | 7.2× | – |
| Altman Z-score | 4.14 (better) | 0.81 |
| Piotroski F-score | 7 (better) | 4 |
| Dividends and buybacks | ||
| Dividend yield | 1.7% | 6.1% (better) |
| Payout ratio | 193% | 348% |
| Years of dividend growth | 0 | 1 (better) |
| Dividend growth, 5Y average | 3.1% (better) | −3.8% |
| Buyback yield | −23.6% | 0.74% (better) |
| Shareholder yield | −21.9% | 6.9% (better) |
| Ownership | ||
| Held by institutions | 103% | 95.9% |
| Held by insiders | 0.63% | 0.34% |
| Insider net buying, 12 months | −$4.6M | −$341K (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 15.5% | 3.3% |
Go deeper
- AHR stock overview
- AHR income statement
- AHR valuation and score
- DOC stock overview
- DOC income statement
- DOC valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.